Q4 Earnings Forecast for argenx Issued By William Blair

argenx SE (NASDAQ:ARGX) – William Blair issued their Q4 2026 earnings per share (EPS) estimates for argenx in a note issued to investors on Monday, March 17th. William Blair analyst M. Minter forecasts that the company will post earnings of $7.29 per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for argenx’s current full-year earnings is $3.13 per share.

argenx (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.60. The company had revenue of $761.22 million for the quarter, compared to analysts’ expectations of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%.

A number of other equities analysts have also commented on ARGX. Citigroup reaffirmed an “outperform” rating on shares of argenx in a research note on Friday, February 28th. Evercore ISI lifted their price objective on argenx from $675.00 to $706.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Robert W. Baird lifted their price objective on argenx from $650.00 to $680.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 4th. Wells Fargo & Company boosted their price target on argenx from $723.00 to $741.00 and gave the company an “overweight” rating in a research note on Friday, February 28th. Finally, Guggenheim boosted their price target on argenx from $775.00 to $1,100.00 and gave the company a “buy” rating in a research note on Monday, March 10th. Three investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, argenx has an average rating of “Moderate Buy” and a consensus price target of $687.00.

argenx Trading Up 1.5 %

NASDAQ:ARGX opened at $614.19 on Tuesday. The stock has a market cap of $37.32 billion, a P/E ratio of -697.94 and a beta of 0.59. The stock’s 50-day moving average is $637.58 and its 200-day moving average is $597.56. argenx has a 1-year low of $349.86 and a 1-year high of $678.21.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ARGX. GeoWealth Management LLC grew its stake in argenx by 56.3% in the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock valued at $31,000 after purchasing an additional 18 shares during the period. Whipplewood Advisors LLC bought a new position in argenx in the 4th quarter valued at $37,000. Global Retirement Partners LLC grew its stake in shares of argenx by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after acquiring an additional 48 shares during the period. FIL Ltd bought a new position in shares of argenx during the 4th quarter worth $38,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of argenx during the 4th quarter worth $38,000. Institutional investors own 60.32% of the company’s stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.